We develop formulations the way pharmaceutical companies develop drugs — minus the disease.
Our methodology is built on three principles: mechanistic rigor, formulation precision, and verification at every stage.
Mechanism first. Marketing never.
We start every formulation by identifying the biological mechanism we're targeting — mitochondrial efficiency, BDNF expression, glutathione recycling, or others. The target comes before the ingredient.
Every active in every formula must have a clear, evidenced mechanism. Not tradition, not trend, not what's selling. If we cannot point to peer-reviewed evidence describing how a molecule acts in human biology, it does not enter our pipeline.
We discard roughly ninety percent of candidate ingredients during this phase. The ones that survive earn their place.
Dose, form, and synergy.
Bioavailability matters more than potency. A premium active that does not absorb is an expensive placebo. We select form factors per molecule — liposomal where needed, microencapsulated where appropriate, sublingual where bioavailability demands it.
Stack synergy is mapped. Every co-active is justified against the formulation's target mechanism. There are no filler ingredients, no proprietary blends, no marketing inclusions.
If we can't test it, we don't ship it.
Identity testing — HPLC, mass spectrometry, orthogonal methods — on every raw material on receipt. No exceptions.
Stability and dissolution testing on every finished product. Independent third-party verification for potency, heavy metals, microbiology, and contaminants. Batch-level certificates of analysis available on request.
What you won't find at Neosoma.
- Proprietary blends that hide doses
- Underdosed "fairy dust" ingredients
- Marketing-driven formulas
- Unstudied novel actives
- Therapeutic claims